Patents by Inventor Christine Tkaczyk

Christine Tkaczyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089699
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 24, 2022
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
  • Publication number: 20220073595
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 10, 2022
    Inventors: Christine TKACZYK, Bret SELLMAN, Martin BORROK, III, Davide CORTI, Andrea MINOLA
  • Publication number: 20210363229
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 25, 2021
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Davide CORTI, Andrea MINOLA
  • Patent number: 11168133
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 9, 2021
    Assignee: MedImmune, LLC
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Taylor Cohen
  • Patent number: 11155606
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 26, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
  • Patent number: 11059884
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: July 13, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Publication number: 20200407429
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Applicant: MedImmune, LLC
    Inventors: Bret SELLMAN, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 10759849
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 1, 2020
    Assignee: MEDIMMUNE, LLC
    Inventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Patent number: 10730934
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 4, 2020
    Assignee: Medlmmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20200109189
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (C1fA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
  • Publication number: 20200109190
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Christine TKACZYK, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Publication number: 20200109191
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: October 11, 2019
    Publication date: April 9, 2020
    Applicant: MedImmune, LLC
    Inventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
  • Publication number: 20200048330
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Application
    Filed: July 24, 2019
    Publication date: February 13, 2020
    Inventors: CHRISTINE TKACZYK, BRET SELLMAN, MARTIN BORROK, III, DAVIDE CORTI, ANDREA MINOLA
  • Patent number: 10457724
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 29, 2019
    Assignee: MedImmune, LLC
    Inventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Publication number: 20190016787
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: January 17, 2019
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret SELLMAN, Christine TKACZYK, Partha S. CHOWDHURY, Lei HUA, Peter PAVLIK, Rebecca BUONPANE, Chew-Shun CHANG
  • Publication number: 20190002540
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: December 18, 2017
    Publication date: January 3, 2019
    Applicant: MedImmune, LLC
    Inventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
  • Patent number: 9879070
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 30, 2018
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 9845348
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 19, 2017
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Patent number: 9527905
    Abstract: Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Lei Hua, Partha Chowdhury, Reena Varkey, Melissa Damschroder, Li Peng, Vaheh Oganesyan, Jamese Johnson Hilliard
  • Publication number: 20160257733
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus-associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: November 5, 2013
    Publication date: September 8, 2016
    Applicant: MEDIMMUNE, LLC
    Inventors: Brett SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA